Xiaozheng Kang

机构：Qilu University of Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, National Cancer Center, Nanjing Drum Tower Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · ORCID：0000-0003-0334-1487

发表论文 142 篇 · 总被引 2311 次 · h-index 23

代表论文

• Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial (2024 · Clinical Cancer Research · 被引 14)
• Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer (2025 · Molecular Therapy · 被引 10)
• In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors (2024 · Molecular Therapy · 被引 7)
• Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2) (2025 · Signal Transduction and Targeted Therapy · 被引 5)
• Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled trial (PALACE-3) (2025 · BMJ Open · 被引 2)
• cfDNA hydroxymethylcytosine profiling for detection metastasis and recurrence of Esophageal Squamous Cell Carcinoma (2025 · World Journal of Surgical Oncology · 被引 2)